Tuesday, July 1, 2025 7/1/2025

PDGFR and KDR Inhibitors for Liver Fibrosis

Award Number: R44DK085771
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/07/2010
PERIOD OF PERFORMANCE END DATE: 08/31/2016

Group Awards By:

View Award Description

PDGFR and KDR Inhibitors for Liver Fibrosis - ¿ DESCRIPTION (provided by applicant): The incidence and prevalence of both alcoholic and non-alcoholic liver diseases is increasing. The population presenting with Metabolic Syndrome, a key risk factor for NAFLD-NASH-liver fibrosis is ballooning. Left untreated, liver fibrosis can progress to cirrhosis or end-stage liver disease and even hepatocellular carcinoma. Today, therapeutic strategies are primarily geared toward mitigating NAFLD-NASH via diet modification, exercise and medication. Unfortunately, there is no approved therapy for established liver fibrosis other than organ transplantation. The proposed translational research program is designed to bring to clinical trials an outstanding and highly promising orally bioavailable small molecule antifibrotic to clinical trials for the treatment of liver fibrosis. Anion Biomedica has identified ANG3070, a potent, highly water-soluble, orally bioavailable, small molecule platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (KDR) inhibitor. Highly compelling data in two models of liver disease speak to antifibrotic activity of this drug candidate. Furthermore, funding for the suite of Investigational New Drug (IND)-enabling safety studies for this drug candidate has been appropriated from the NIH and DoD. The proposed SBIR Phase II program seeks to obtain dose efficacy information for ANG3070 in two dietary models of liver disease which simulate to some extent the human NAFLD-NASH-liver fibrosis phenotype. Efficacy data from this study, together with the safety data will determine drug therapeutic index and form the form the basis of an IND submission to FDA to bring this drug to clinical trials. 1


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2017 ( Subtotal = $0 )
2017	2014	ANGION BIOMEDICA CORP.	51 CHARLES LINDBERGH BLVD	UNIONDALE	NY	11553	NASSAU	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	2	2/14/2017	COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2014 ( Subtotal = $769,978 )
2014	2014	ANGION BIOMEDICA CORPORATION	350 COMMUNITY DRIVE	MANHASSET	NY	11030	NASSAU	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	2	9/8/2014	COMPETING CONTINUATION	$769,978
														Subtotal = $769,978

Grand Total All Awards = $769,978

Top

All Categories

About

Search

Reports

Data Submission

Award Information

PDGFR and KDR Inhibitors for Liver Fibrosis

Award Number: R44DK085771

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/07/2010

PERIOD OF PERFORMANCE END DATE: 08/31/2016

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer